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Abstract: Synthesis of a novel Combretastatin A-4 analogue using Schiff’s reaction of benzil and 4-aminoantipyrine has been achieved under 
solvent free conditions. The structure of compound was examined spectroscopically and confirmed from single crystal diffraction studies. The 
synthesized Combretastatin A-4 analogue was investigated for its DNA binding ability as the plausible mechanism for its antitumor activity. The 
binding propensity of the synthesized compound with calf-thymus (CT) DNA was monitored with absorption and emission spectrophotometric 
titrations. The calculations predict a binding constant of 7.24 × 104 for the complex of the synthesized compound with CT DNA which is com-
parable in magnitude to that of DNA binding of bactericidal drug enoxacin and typical intercalation indicator ethidium bromide (EB). Competi-
tive binding studies of the synthesized compound with EB using fluorescence titration reveal that it displaces the DNA-bound EB and binds in 
intercalative mode which was further supported by circular dichroism (CD) spectroscopy. The probable site and binding energy of the com-
pound with DNA was further theoretically investigated by molecular docking studies. The significant DNA binding ability of the synthesized 
Combretastatin A4 analogue as revealed from this study could be related to the anticancer activity of the Combretastatin A4. 
 





YNTHESIS of specially designed compounds for specific 
applications through an environmentally benign meth-
odology is one of the contemporary challenges.[1] 4-Amino-
antipyrine belongs to the class of phenazones, a predo-
minantly useful heterocyclic compounds, known for their 
significant role in organic synthesis[2] and diverse biological 
activity.[3] Benzil (an aromatic 1,2 diketone) is a common 
building block in organic synthesis which is also reported to 
be a strong inhibitor of mammalian carboxylesterase enzy-
mes.[4] Recently metabolic enzyme expression has been 
linked to metabolic alterations which are being regarded as 
a hallmark of cancer.[5] In continuation of our work on anti 
cancer compounds[6–10] a schiff base of benzil and 4-amino-
antipyrine - the two privileged molecules of drug dev-
elopment was designed. The motivation for selecting ben-
zil amongst a plethora of aromatic 1,2 diketones is its 
prominent resemblance to anticancer natural product 
Combretastatin (Figure 1) which has served as a funda-
mental scaffold for the synthesis of large number of 
compounds with antitumor activity.[11,12] The presence of S 
 
Figure 1. Structural resemblance of Compound 1 with 
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two aryl rings with hydrogen bonding groups and the re-
stricted rotation about the olefinic bridge in Com-
bretastatin is considered crucial for their anticancer 
activity.[13] The benzil moiety in the synthesized schiff base 
(compound 1) has two aryl rings, hydrogen bonding car-
bonyl group and restricted rotation due to the bulky antipy-
rine group, hence the synthesized compound 1 has a close 
resemblance to the pharmacophore of the Combretastatin. 
Since DNA is considered to be a primary target of most of 
the anticancer compounds and essentially based on the 
idea that compounds with planar aromatic rings are known 
to be its intercalators[14] an investigation of DNA binding 
propensity of synthesized compound was evaluated using 
different biophysical methods.[15] Even though DNA binding 
ability of a vast number of compounds has been re-
ported,[16,17] the point of interest in this study is metal free 
DNA binding ability of a natural product analogue synthe-




All reagents and solvents used (4-aminoantipyrine, benzil, 
dichloromethane, methanol) were of analytical grade ob-
tained from Sigma-Aldrich Chemicals Pvt. Ltd. and were 
used without further purification. The calf Thymus DNA was 
purchased from Bangalore Genei, (India). Silica gel coated 
aluminum plates were used for TLC monitoring of reactions. 
The synthesized Schiff base compound was soluble at room 
temperature in Tris-HCl buffer (pH = 7.2) in presence of 1 % 
DMSO solution. All the experimental solutions and dilutions 
of compound 1 were done using the Tris-HCl buffer (pH = 
7.2) in presence of 1 % DMSO solution. The stock solution 
of CT-DNA was prepared in Tris-HCl buffer (pH = 7.2) stored 
at 4 °C and consumed within 2 days.  
Instrument and physical measurements 
The IR spectrum was recorded as KBr pellet on Shimadzu IR-
408 Perkin-Elmer 1800 (FTIR) spectrophotometer and the 
values are given in cm–1. Elemental analysis (C, H, N) was 
performed using Carlo Erba analyzer model 1108. An HR 
ESI-MS spectrum was recorded on G6540-UHD LC/MS Q-
TOF (Agilent Technologies). 1H NMR spectra were recorded 
on Bruker-Avance DPX FT-NMR 400 MHz spectrometer with 
TMS as an internal standard. The single crystal X ray struc-
ture was obtained using X’calibur CCD area-detector dif-
fractometer. The UV-Vis measurements were recorded on 
a 177 Beckman DU 40 Spectrophotometer (USA) using a cu-
vette of 1 cm path length. Fluorescence measurements were 
recorded on a Shimadzu 184 Spectrofluorimeter -5000 
(Japan) spectra in the range of 200–330 nm around 25 °C. The 
CD spectra were collected using a Jasco J-815 Circular 
dichroism (CD) Spectropolarimeter. The geometries were 
optimized with the Gaussian 03 quantum chemistry 
package using Becke’s three parameter hybrid functional 
(B3LYP) and the 6-311G (d,p) ++ basis set. The rigid molec-
ular docking studies were performed using HEX 6.1 soft-
ware. The Hex 6.1 performs protein docking using Spherical 
Polar Fourier Correlations, which needs the ligand and the 
receptor input in PDB format. 
General Procedure 
Synthesis of 1,5-Dimethyl-4-(2-oxo-1,2-diphenyl-ethylidene-
amino)-2-phenyl-1,2-dihydro-pyrazol-3-one Compound 1: 
 The compound 1 was synthesized by fusion of 1:1 
molar ratio of 4-aminoantipyrine and benzil. The solid 4-
aminoantipyrine was first melted over silicone oil bath 
maintained around 110 °C followed by slow addition of 
solid benzil (m.p. 97 °C) to the molten state of 4-aminoanti-
pyrine. The reaction mixture was stirred over a magnetic 
stirrer for 1 h and the progress of reaction was monitored 
using TLC. After completion of reaction yellow colored solid 
product got separated, which was filtered, air dried and re-
crystallized from methanol and dichloromethane (4 :1) sol-
vent mixture as pale yellow crystals. Yield: 74 %; m.p. 145–
47 °C. IR (KBr) cm–1 1650, 1550 and 1590 cm–1. 1H NMR (CDCl3, 
400 MHz): δ/ppm 7.55–7.41 (m, 4H), 7.41–7.29 (m, 8H), 7.27–
7.17 (m, 3H), 3.03 (s, 3H), 2.36 (s, 3H). HR ESI-MS (m/z) calcd. 
for C25H21N3O2 [M+H]+ 396.1707, found 396.1721. Anal. Calcd. 
mass fractions of elements, w/ % for C25H21N3O2: C 75.93,  
H 5.35, N 10.63; found: C 76.58, H 4.93, N 9.87. 
Crystal Structure Determination and 
Refinement 
The X-ray intensity data of 8516 reflections (of which 4083 
unique) were collected on X’calibur CCD area-detector dif-
fractometer equipped with graphite monochromated Mo-
Kα radiation (λ = 0.71073 Å). The dimension of crystal used 
for data collection was 0.30 × 0.20 × 0.20 mm. The cell di-
mensions were determined by least-squares fit of angular 
settings of 2842 reflections in the θ range 3.81 to 28.85 °. 
The intensities were measured by ω scan mode for θ ranges 
3.56 to 26.00 °. 2755 reflections were treated as observed: 
I > 2ζ(I). The structure was solved by direct methods using 
SHELXL 97. All non-hydrogen atoms of the molecule were 
located in the best E-map. Full-matrix least-squares refine-
ment was carried out using SHELXL 97. The final refinement 
cycles converged to R = 0.0441 and wR (F2) = 0.1113 for the 
observed data. Residual electron densities ranged from - 
0.215 to 0.203 Å–3. Atomic scattering factors were taken 
from International Tables for X-ray Crystallography (1992, 
Vol. C, Tables 4.2.6.8 and 6.1.1.4). The crystallographic data 
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Preparation of DNA Stock Solution  
The stock solution of DNA was prepared by dissolving CT 
DNA in Tris-HCl buffer (30 mM, pH = 7.2). The purity of DNA 
was verified by monitoring the ratio of absorbance at 260 
nm to that at 280 nm, which was in the range of 1.8–1.9. 
The concentration of the DNA was determined spectropho-
tometrically using ε = 6600 mol L–1cm–1.[18] 
Absorption Spectrometry 
The absorbance value of the compound 1 was recorded in the 
absence and presence of DNA in the range of 225–550 nm. 
The reference solution was the corresponding Tris-HCl buffer 
solution. While measuring the absorption spectra, equal 
amount of DNA was added to both the compound and refer-
ence solutions to eliminate the absorbance of DNA itself.  
Emission Spectroscopy 
The binding constants Kb of the compound (1) with 
DNA was obtained by the fluorescence titration method. 
The fluorescence quenching with increasing concentration 
of DNA was recorded after exciting the compound solution 
at 290 nm, using 10/10 nm slit widths. 
Circular Dichroism (CD) Studies 
The CD spectra were recorded in the region of 330–200 nm 
with a scan speed of the 200 nm/min in a cuvette of 2 mm 
path length. Three scans were recorded and averaged. 
Viscosity Studies 
The viscosity measurements were carried out using Oswald 
capillary viscometer. The flow time was measured with a 
digital stopwatch, and each sample was tested three times 
to get an average calculated time. The data were presented 
as (η/η0)⅓ versus concentrations of DNA/compound 1 a ratio 
where η is the viscosity of the solution in the presence of a 
compound 1; η0 is the viscosity of the DNA solution only. 
Molecular Docking Experiments 
The rigid molecular docking studies were performed using 
HEX 6.1 software. The crystal structure of the B-DNA do-
decamer d(CGCGAATTCGCG)2 (PDB ID: 1BNA) was down-
loaded from the protein data bank. The energy optimized 
structure of compound 1 was used for the docking study. 
Visualization of the docked pose has been done by using 
PyMol (http://pymol.sourceforge.net/) molecular graphic 
program. 
 
RESULTS AND DISCUSSION 
The conventional synthesis employs refluxing reactant mix-
tures in high boiling organic solvents, followed by extensive 
chromatographic workup of purification and re-crystalliza-
tion. At present environmentally benign synthetic methods 
are receiving considerable attention and solvent-free pro-
tocols are in demand. While embracing the principles of  
Table 1. Crystal data and structure refinement parameters of Compound 1 
CCDC No 957471 
Crystal description Block, Yellow 
Empirical formula C25H21N3O2 
Formula weight 395.45 
Radiation wavelength Mo-Kα (λ = 0.71073 Å) 
Temperature. 293(2) K 
Unit cell dimensions a = 9.8747(4) Å            α = 90 ° 
 b = 14.0319(8) Å          β = 90.568(4) ° 
 c = 15.0386(7) Å           γ = 90 ° 
Crystal system; Space group Monoclinic; P121/n1 
Unit cell volume 2083.66(18) Å3 
Z 4 
Absorption coefficient 0.081mm–1 
F(000) 832 
θ range for entire data collection –3.56 ° < θ < 26.0 ° 
Range of indices –17 to 9, l = –18 to 17 
Reflections collected / unique 8516 / 4083 
Reflections observed (I > 2σ(I)) 2755 
Refinement Full-matrix least-squares on F2 
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green chemistry,[19] we attempted a solvent free target 
synthesis, of a hitherto unknown compound 1. It was 
synthesized by condensing of equimolar quantities of 4-
amino antipyrine and benzil as shown in Scheme 1. The 
synthesis involves a one pot, single step, solvent free reac-
tion using non–conventional fusion method in which the re-
actant with higher melting point (4-aminoantipyrine, m.p. 
110 °C) was first liquefied (melted) and the other with lower 
melting point (benzil, 97 °C) was added to the molten state 
of former. Thus, equimolar amounts of 4-aminoantipyrine 
and benzil were condensed under solvent less conditions at 
110 °C in a silicone oil bath and the reaction mixture was 
magnetically stirred for 1 h. The compound 1 was crystal-
lized by s low solvent evaporation method using methanol 
and dichloromethane (4 :1) mixture. 
 The structure of the synthesized compound 1 was 
elucidated by IR, 1H NMR, Mass spectrometry and Ele-
mental (CHN) analysis, which was also unambiguously con-
firmed through single crystal X-ray crystallographic study. 
An ORTEP view of the compound with atomic labeling is 
shown in (Figure 2). The geometry of the molecule was cal-
culated using the WinGX, PARST and PLATON softwares. 
The extended structure of the compound 1 shows weak in-
termolecular interactions like π–π stacking, C–H–π, C–H–O 
and C–H–N type intermolecular interactions (Figure 3). The 
crystallographic data is summarized in Table 1. The meas-
ured π–π distances of 3.704 and 3.253 Å respectively sug-
gests π–π stacking and C–H–π interaction.[20,21] The 
distances of 2.614 and 2.734 Å respectively indicate a good 
hydrogen bonding of phenyl hydrogen with carbonyl oxy-
gen and nitrogen atoms in compound 1. 
DNA binding studies 
 
ABSORPTION SPECTRAL STUDIES 
The Uv-visible absorption spectra of compound 1 exhibits 
intense absorption bands at 290 nm and a shoulder at 400 
nm attributed to π–π* and nπ* intraligand transition, re-
spectively. The hypochromism or decrease in absorption in-
tensity of the compound 1 observed on gradual addition of 
CT DN A (0.00–6.50 × 10–5 mol L–1) to its fixed concentra-
tion(1.11 × 10–4 mol L–1) (Figure 4), was attributed to inter-
action of its π* molecular orbitals with the π-orbitals of the 
DNA base pairs, resulting in a decreased π–π* transition 
probability and hence hypochromism.[22] The binding con-
stant Kb quantifying binding propensity of compound 1 
with CT DNA, was obtained from the change in the absorb-
ance spectra with increasing concentrations of CT DNA. The 
binding constant of 7.24 × 104 mol L–1 was calculated from 
the ratio of slope to the intercept in the inset plot of (Figure 





( ) )(a f b b fbfε ε ε εKε ε  
   (1) 
 
where [DNA] is the concentration of DNA in base pairs, and 
εa is the apparent extinction coefficient (Aabs / [compound 
1], εf is the extinction coefficient of the compound 1 when 
free in solution and εb is its extinction coefficient when fully 
 
Figure 3. Intermolecular forces of attraction in Compound 1. 
 
Figure 2. ORTEP view of the Compound 1 with displacement 
ellipsoids drawn at 50%. H atoms are shown as unlabelled 
white spheres of arbitrary radii. 
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bound to DNA. A plot of [DNA] / (εa – εf) versus [DNA] gave 
a slope 1 / (εb – εf) and Y axis intercept equal to 1 / Kb(εb – εf) 
respectively. Thus intrinsic binding constant Kb was calcul-
ated from the ratio of the slope to the Y axis intercept. 
 The calculated magnitudes of Kb indicate a consider-
able binding affinity of compound 1 for CT DNA. The ob-
served absorption spectral changes are predictive of 
intercalative mode of interaction of compound 1 with CT 
DNA involving insertion of its aromatic rings between the 
base pairs of DNA. In order to arrive at the exact mode of 
interaction we further investigated the DNA binding exper-
iments using other techniques. 
 
EMISSION SPECTRAL STUDIES  
The compound 1 on excitation at 290 nm emits at 374 nm 
in the absence of CT DNA. The fluorescence intensity in-
creased with no apparent change in shape and the slight 
change in position of the emission band (4 nm) on gradual 
addition of CT DNA (0.00–3.0 × 10–5 mol L–1 ) to a fixed con-
centration of compound 1 (1.0 × 10–5 mol L–1 ) (Figure 5). The 
hyperchromism in fluorescence intensity of the compound 
1 establishes its binding interaction with CT-DNA most 
probably due to the inaccessibility of solvent water mole-
cules to reach the hydrophobic environment inside the DNA 
helix and the restricted mobility of the compound at the 
binding site leading to a decrease in vibrational mode of relaxa-
tion.[24] The binding constant value of 7.29 × 104 mol L–1 deter-
mined from the Scatchard equation [25] depicts the significant 
interaction between the compound 1 and CT DNA in compa-
rison to the reported binding constant (6.58 × 104 mol L–1) of a 
well known DNA intercalator ethidium bromide.[26]  
 
COMPETITIVE DNA-BINDING WITH 
ETHIDIUM BROMIDE (EB)  
Ethidium bromide (EB, 3,8-diamino-5-ethyl-6-phenyl-phe-
nanthridinium bromide) is a typical intercalator. A compet-
itive binding experiment of compound 1 with EB was 
carried out to ascertain its intercalative mode of DNA inter-
action. EB on chelation with DNA gives an intense fluores-
cence however when freed from DNA, EB does not show 
any noticeable emission. In the competitive binding experi-
ments, the emission spectra of EB-DNA adduct at 595 nm  
 
Figure 5. Emission spectral changes for a fixed concentration
of the compound 1 upon addition of increasing amounts of 
CT DNA.in 30 mM Tris-HCl buffer pH = 7.2. [DNA] = 0.00 –
3.0 × 10–5 mol L–1, [Compound 1] = 1.0 × 10–5 mol L–1. 
 
 
Figure 6. Fluorescence titration of EB-CT DNA complex with  
compound 1; [DNA]= [EB]= 1.0 x 10–5 mol L-1. Arrow shows 
change in intensity with increasing concentration of 
compound 1 (0.00 – 5.0 × 10–5 mol L–1). 
 
 
Figure 4. Absorption spectral changes for a fixed concen-
tration of compound 1 upon addition of increasing amounts 
of CT DNA in 30 mM Tris HCl buffer pH = 7.2. Inset: Plots of 
[DNA]/ (a–f) (in mol2 L–2 cm) vs. [DNA] for the titration with 
compound 1.,  experimental data points, full lines, linear 
fitting of the data. [DNA] = 0.00–6.50 × 10–5 mol L–1, 
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(λex = 332 nm) in the absence and presence of compound 1 
have been recorded. With increasing addition of compound 
1 to EB-DNA adduct from the ratio of 1 :1 to 5 :1, a decrease 
in the emission intensity of EB-DNA system was observed 
indicating competition between EB and compound 1 to-
wards CT-DNA (Figure 6). The significant quenching of EB-
DNA fluorescence suggests that compound 1 displaces EB 
from the EB-DNA complex and thus interacts with CT DNA 
in the intercalative mode at the similar binding site. The flu-
orescence quenching data were analyzed to obtain the 
quenching constant using Stern-Volmer equation, 
 F0 / F = 1 + KSV.[Q] (2) 
Where F0 and F denote the steady-state fluorescence inten-
sities in the absence and presence of the quencher (com-
pound 1), respectively, KSV is the Stern-Volmer quenching 
constant and [Q] is the concentration of the quencher. The 
[Eq. (2)] was applied to determine KSV by linear regression 
of a plot of (F0 /F) – 1 versus concentration of compound 1. 
The Ksv value for the compound 1 was found to be 2.88 × 
104 mol L–1 which is consistent with the electronic absorp-
tion results. Comparing the intercalative binding potential 
of compound 1 with a well known anti-inflammatory drug 
Naproxen [27] reveals that it brings more quenching of EB-DNA 
fluorescence even at a lower concentration than naproxen, 
which confirms the good intercalative binding of compound 1. 
 
CIRCULAR DICHROISM (CD) STUDIES 
The covalent binding and intercalation with a drug influ-
ence the tertiary structure of DNA and lead to changes in its 
circular dichroism (CD) spectra.[28] We used CD spectros-
copy to identify any change in the structure of the CT DNA 
upon binding with compound 1. The CD spectrum of CT 
DNA in Tris-buffer at pH = 7.2 (Figure 7), depicts a positive 
absorption band at 275 nm (band I) and, negative absorp-
tion (band II) at 245 nm due to π–π base stacking and right 
hand helicity respectively, which is consistent with the char-
acteristic B conformation of DNA.[29] With the sequential 
addition of compound 1 (0.4 – 2.4 × 10–5 mol L–1) to a fixed 
concentration of DNA (2.0 × 10–5 mol L–1 ), the intensity of 
275 nm band got increased while that of 245 nm band went 
down (from –2 to –6). The changing intensities of two bands 
result in the formation of isodichroic point at 260 nm sug-
gesting single complex formation between CT-DNA and 
compound 1. The change in the ellipticity at 275 nm can be 
explained on the basis of disruption of the stacked bases in 
order to maximize intercalation of the compound 1 with CT 
DNA. The change at 245 nm occurs due to change in the 
hydration layer of DNA, which in turn affects the helicity of 
DNA. Thus the type of changes in the CD spectra reflect 
base stacking interactions through intercalation of com-
pound 1.[30] A slight increase in negativity of the band at 211 
nm can be due to a partial B to C-DNA conformational tran-
sition of compound 1–DNA adduct as recently reported by 
Marty et al.[31] 
 
VISCOSITY STUDIES 
In classical intercalation the DNA helix lengthens as the 
base pairs are separated to accommodate the bound ligand 
leading to increased DNA viscosity. Whereas, a partial, non-
classical ligand intercalation causes a bend in DNA helix re-
ducing its effective length and thereby its viscosity.[32] A plot 
of relative viscosities (η/η0)1/3 versus [compound 1] / [DNA] 
was obtained to study any change in viscosity of DNA solu-
tion in presence of the increasing molar ratios of compound 
1 to DNA. As illustrated in Figure 8, on increasing the molar 
ratios of the compound 1 to DNA (0.0, 0.2, 0.4, 0.6, 0.8, and 
1.0), the relative viscosity of compound-DNA increases 
steadily, which proves that the compound binds to CT DNA 
 
Figure 7. CD spectral changes for a fixed concentration 
of CT DNA with increasing concentration of synthesized 
compound 1 in 30 mM Tris-HCl buffer pH = 7.2. [DNA] = 2.0 
× 10–5 mol L–1 [Compound 1] = (0.4 – 2.4 × 10–5 mol L–1). 
 
 
Figure 8. Change in viscosity of CT DNA with increasing con-
centration of compound1. Effect of increasing amount of com-
pound 1 on the relative viscosities (η/η0) of CT-DNA at 25 °C in 
Tris-HCl buffer at pH = 7.2 [CT-DNA] = [compound 1] = 0.1 × 
10–3 mol L–1 and the molar ratios of compound 1 / EB to DNA 
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by intercalation. The increase in relative viscosity upon ad-
dition of compound 1 to CT DNA solution, causes the axial 
length of the DNA to increase, which corroborates the in-
tercalating tendency of compound 1. 
 
MOLECULAR DOCKING STUDIES  
Computational studies through molecular docking are an 
attractive tool to probe the mechanistic details[33] and 
mode of interaction between biopolymers and bioactive 
compounds. Docking studies were attempted to establish 
the type and the magnitude of interaction between  
the compound 1 and the CT DNA. In our experiments rigid  
molecular structure of DNA duplex with a sequence 
d(CGCGAAT TCGCG)2 dodecamer (PDBID : 1BNA) was ta-
ken, the finest fit orientation, and the lowest energy docked 
structure was analyzed. The study revealed that, initially 
compound 1 interacts with DNA via an electrostatic mode 
involving outside edge stacking interactions with the 
oxygen atom of the phosphate backbone of DNA. The 
docked structures shown in Figure 9 corroborate well  
with the experimental results and clearly indicate that  
the compound 1 fits snugly into the curved contour of the 
targeted DNA in the minor groove and is situated within a 
G–C rich region, thus leading to Van der Waals interaction 
and hydrophobic contacts with the DNA functional groups 
that define the groove.[34] In addition to this the phenyl ring 
of the compound 1 is arranged in an intercalative manner 
between the G10A and C11A of strand A of the DNA double 
helix. In this configuration, the N14 of the compound re-
mains inclined towards the phosphodiester bond of DNA 
and hence the possibility of hydrogen bonding cannot be 
ruled out. The resulting relative binding energy of docked 
compound–DNA complex was found to be 226.52 kJ mol−1. 
High value of the binding energy indicates π–π type of pos-
sible interaction between the phenyl ring of the compound 
1 and the nucleotide base pairs of DNA in addition to the 
electrostatic and Vander Waals interaction.[35] From the 
docking study, it can be concluded that binding studies of 
such type of molecules with DNA is credible and further 
work in this direction, is in progress. 
 
CONCLUSIONS 
In summary, a novel Combretastatin A4 analogue, com-
pound 1, was synthesized under solvent free conditions us-
ing benzil and 4-aminoantipyrine. The compound 1 was 
spectroscopically examined and structurally characterized 
by single crystal X ray diffraction study. The CT DNA binding 
propensity of the compound 1 was investigated by different 
biophysical methods of DNA binding (fluorescence, elec-
tronic absorption, ethidium bromide replacement, CD spec-
troscopy, viscosity measurement and molecular docking 
studies). The DNA binding protocols undertaken in the pre-
sent work were in agreement, with the primary intercala-
tive mode of DNA binding for compound 1. The significant 
DNA binding ability of compound 1 suggests, the possibility 
of DNA binding as the plausible mechanism of the Com-
bretastatin anticancer activity. Furthermore, studies aimed 
at the targeted syntheses of electronically delocalized and 
sterically pre-organized Combretastatin analogues for ex-
ploration as DNA target agents and in the development of 
new cancer therapeutics is underway in our laboratory. 
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